Targeting aberrant DNA methylation across subtypes of pediatric high-grade glioma inhibits tumor growth and RUNX3 represents a targetable methylated tumor suppressor
Authors:
Open Access
- 27 March 2026
- journal article
- research article
- Published by Springer Nature in Cell Communication and Signaling
- Vol. 24 (1)
Abstract
Aberrant DNA methylation is one of the most prevalent epigenetic alterations in cancer, and reversing DNA methylation holds promise as a therapeutic strateKeywords
Funding Information
- Guangxi Young and Middle-aged University Teacher’ Research Ability Enhancement Project (2025KY0158)
- The National Science and Technology Major Project of the Ministry of Science and Technology of China (No.2022YFC2705002)
- National Natural Science Foundation of China (No.82072795)
- National Natural Science Foundation of China (No.82573712)
This publication has 33 references indexed in Scilit:
- Single substitution in H3.3G34 alters DNMT3A recruitment to cause progressive neurodegenerationCell, 2023
- Response assessment in paediatric high-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working groupThe Lancet Oncology, 2020
- Mutant ACVR1 Arrests Glial Cell Differentiation to Drive Tumorigenesis in Pediatric GliomasCancer Cell, 2020
- Infusion of 5-Azacytidine (5-AZA) into the fourth ventricle or resection cavity in children with recurrent posterior Fossa Ependymoma: a pilot clinical trialJournal of Neuro-Oncology, 2018
- Glioma epigenetics: From subclassification to novel treatment optionsSeminars in Cancer Biology, 2018
- DNA methylation-based classification of central nervous system tumoursNature, 2018
- 5-Hydroxymethylcytosine localizes to enhancer elements and is associated with survival in glioblastoma patientsNature Communications, 2016
- Integrative analysis of 111 reference human epigenomesNature, 2015
- The RUNX family: developmental regulators in cancerNature Reviews Cancer, 2015
- Epigenetics in human gliomasCancer Letters, 2014